Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...

Suzetrigine is under clinical development by Vertex Pharmaceuticals and currently in Phase III for Diabetic Peripheral Neuropathy. According to GlobalData, Phase III drugs for Diabetic Peripheral ...

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corp. (TM) and Vertex Pharmaceuticals Inc. (VRTX), as well as two micro ...